{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:06:30Z","timestamp":1792076790230,"version":"4.4.0"},"reference-count":50,"publisher":"National Academy of Sciences","issue":"45","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["200187\/Z\/15\/Z"],"award-info":[{"award-number":["200187\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["206579\/Z\/17\/Z"],"award-info":[{"award-number":["206579\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004815","name":"Isaac Newton Trust","doi-asserted-by":"publisher","award":["17.37(r)"],"award-info":[{"award-number":["17.37(r)"]}],"id":[{"id":"10.13039\/501100004815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health","doi-asserted-by":"publisher","award":["10064"],"award-info":[{"award-number":["10064"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,11,6]]},"abstract":"<jats:p>Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have not yielded resistant viruses. Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a laboratory setting. We found that two mutations were required for robust resistance to favipiravir. We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture. This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase. K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F. The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.<\/jats:p>","DOI":"10.1073\/pnas.1811345115","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T15:40:50Z","timestamp":1540309250000},"page":"11613-11618","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":293,"title":["The mechanism of resistance to favipiravir in influenza"],"prefix":"10.1073","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5963","authenticated-orcid":false,"given":"Daniel H.","family":"Goldhill","sequence":"first","affiliation":[{"name":"National Infection Service, Public Health England, London NW9 5EQ, United Kingdom;"},{"name":"Section of Molecular Virology, Imperial College London, London W2 1PG, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aartjan J. W.","family":"te Velthuis","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Pathology, Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge CB2 2QQ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Section of Molecular Virology, Imperial College London, London W2 1PG, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Langat","sequence":"additional","affiliation":[{"name":"Section of Molecular Virology, Imperial College London, London W2 1PG, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zambon","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London NW9 5EQ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Lackenby","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London NW9 5EQ, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-0895","authenticated-orcid":false,"given":"Wendy S.","family":"Barclay","sequence":"additional","affiliation":[{"name":"Section of Molecular Virology, Imperial College London, London W2 1PG, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"e_1_3_4_1_2","unstructured":"; WHO Influenza (Seasonal) Factsheet . Available at www.who.int\/mediacentre\/factsheets\/fs211\/en. Accessed February 22 2018. (2018)."},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt AC","year":"2014","unstructured":"AC Hurt, The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 8, 22\u201329 (2014).","journal-title":"Curr Opin Virol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright RA","year":"2006","unstructured":"RA Bright, DK Shay, B Shu, NJ Cox, AI Klimov, Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295, 891\u2013894 (2006).","journal-title":"JAMA"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jama.2009.324","article-title":"The evolution of influenza resistance and treatment","volume":"301","author":"Weinstock DM","year":"2009","unstructured":"DM Weinstock, G Zuccotti, The evolution of influenza resistance and treatment. JAMA 301, 1066\u20131069 (2009).","journal-title":"JAMA"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM200302273480923","article-title":"Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient","volume":"348","author":"Weinstock DM","year":"2003","unstructured":"DM Weinstock, LV Gubareva, G Zuccotti, Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 348, 867\u2013868 (2003).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","article-title":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08","volume":"15","author":"Hauge SH","year":"2009","unstructured":"SH Hauge, S Dudman, K Borgen, A Lackenby, O Hungnes, Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15, 155\u2013162 (2009).","journal-title":"Emerg Infect Dis"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom JD","year":"2010","unstructured":"JD Bloom, LI Gong, D Baltimore, Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328, 1272\u20131275 (2010).","journal-title":"Science"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: What does the future hold?","volume":"48","author":"Hayden F","year":"2009","unstructured":"F Hayden, Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 48, S3\u2013S13 (2009).","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta Y","year":"2013","unstructured":"Y Furuta, , Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100, 446\u2013454 (2013).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta Y","year":"2017","unstructured":"Y Furuta, T Komeno, T Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93, 449\u2013463 (2017).","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta Y","year":"2002","unstructured":"Y Furuta, , In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46, 977\u2013981 (2002).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta Y","year":"2005","unstructured":"Y Furuta, , Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49, 981\u2013986 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso M","year":"2010","unstructured":"M Kiso, , T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107, 882\u2013887 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell RW","year":"2007","unstructured":"RW Sidwell, , Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51, 845\u2013851 (2007).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1128\/AAC.01739-09","article-title":"In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses","volume":"54","author":"Sleeman K","year":"2010","unstructured":"K Sleeman, , In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54, 2517\u20132524 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa H","year":"2013","unstructured":"H Sangawa, , Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57, 5202\u20135208 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens L","year":"2013","unstructured":"L Naesens, , Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 84, 615\u2013629 (2013).","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee DF","year":"2010","unstructured":"DF Smee, , Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54, 126\u2013133 (2010).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice","volume":"6","author":"Marathe BM","year":"2016","unstructured":"BM Marathe, , Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep 6, 26742 (2016).","journal-title":"Sci Rep"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich L","year":"2014","unstructured":"L Oestereich, , Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105, 17\u201321 (2014).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever","volume":"213","author":"Oestereich L","year":"2016","unstructured":"L Oestereich, , Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213, 934\u2013938 (2016).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang L","year":"2018","unstructured":"L Delang, R Abdelnabi, J Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 153, 85\u201394 (2018).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e26437","DOI":"10.7554\/eLife.26437","article-title":"A novel twelve class fluctuation test reveals higher than expected mutation rates for influenza A viruses","volume":"6","author":"Pauly MD","year":"2017","unstructured":"MD Pauly, MC Procario, AS Lauring, A novel twelve class fluctuation test reveals higher than expected mutation rates for influenza A viruses. eLife 6, e26437 (2017).","journal-title":"eLife"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert A","year":"2016","unstructured":"A Stevaert, L Naesens, The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design. Med Res Rev 36, 1127\u20131173 (2016).","journal-title":"Med Res Rev"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich T","year":"2013","unstructured":"T Baranovich, , T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87, 3741\u20133751 (2013).","journal-title":"J Virol"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1254\/jphs.14156SC","article-title":"Characterization of susceptibility variants of influenza virus grown in the presence of T-705","volume":"126","author":"Daikoku T","year":"2014","unstructured":"T Daikoku, Y Yoshida, T Okuda, K Shiraki, Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J Pharmacol Sci 126, 281\u2013284 (2014).","journal-title":"J Pharmacol Sci"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1111\/evo.13041","article-title":"An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy","volume":"70","author":"Bank C","year":"2016","unstructured":"C Bank, , An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy. Evolution 70, 2470\u20132484 (2016).","journal-title":"Evolution"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden E","year":"2016","unstructured":"E Vanderlinden, , Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60, 6679\u20136691 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/gbe\/evx138","article-title":"The combined effect of oseltamivir and favipiravir on influenza A virus evolution","volume":"9","author":"Ormond L","year":"2017","unstructured":"L Ormond, , The combined effect of oseltamivir and favipiravir on influenza A virus evolution. Genome Biol Evol 9, 1913\u20131924 (2017).","journal-title":"Genome Biol Evol"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita E","year":"2016","unstructured":"E Takashita, , Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res 132, 170\u2013177 (2016).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/ncomms5794","article-title":"Generation and characterization of influenza A viruses with altered polymerase fidelity","volume":"5","author":"Cheung PP","year":"2014","unstructured":"PP Cheung, , Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5, 4794 (2014).","journal-title":"Nat Commun"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"e00323-17","DOI":"10.1128\/mSphere.00323-17","article-title":"Epistatic interactions within the influenza A virus polymerase complex mediate mutagen resistance and replication fidelity","volume":"2","author":"Pauly MD","year":"2017","unstructured":"MD Pauly, DM Lyons, WJ Fitzsimmons, AS Lauring, Epistatic interactions within the influenza A virus polymerase complex mediate mutagen resistance and replication fidelity. MSphere 2, e00323-17 (2017).","journal-title":"MSphere"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang L","year":"2014","unstructured":"L Delang, , Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69, 2770\u20132784 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/AAC.01073-16","article-title":"In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71","volume":"60","author":"Wang Y","year":"2016","unstructured":"Y Wang, , In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob Agents Chemother 60, 5357\u20135367 (2016).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1743-422X-7-257","article-title":"Population dynamics of an RNA virus and its defective interfering particles in passage cultures","volume":"7","author":"Thompson KAS","year":"2010","unstructured":"KAS Thompson, J Yin, Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol J 7, 257 (2010).","journal-title":"Virol J"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","unstructured":"D Goldhill Determining the mutation bias of favipiravir in influenza using next-generation sequencing. bioRxiv:10.1101\/375378. Preprint posted July 23 2018. (2018).","DOI":"10.1101\/375378"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1073\/pnas.1232294100","article-title":"A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity","volume":"100","author":"Pfeiffer JK","year":"2003","unstructured":"JK Pfeiffer, K Kirkegaard, A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100, 7289\u20137294 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"20166","DOI":"10.1073\/pnas.1110064108","article-title":"Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID","volume":"108","author":"Jabara CB","year":"2011","unstructured":"CB Jabara, CD Jones, J Roach, JA Anderson, R Swanstrom, Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 108, 20166\u201320171 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_39_2","article-title":"Initiation, elongation and realignment during influenza virus mRNA synthesis","author":"Te Velthuis AJW","year":"2017","unstructured":"AJW Te Velthuis, J Oymans, Initiation, elongation and realignment during influenza virus mRNA synthesis. J Virol, November 15, 2017).","journal-title":"J Virol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature14008","article-title":"Structure of influenza A polymerase bound to the viral RNA promoter","volume":"516","author":"Pflug A","year":"2014","unstructured":"A Pflug, D Guilligay, S Reich, S Cusack, Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516, 355\u2013360 (2014).","journal-title":"Nature"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"te Velthuis AJW","year":"2014","unstructured":"AJW te Velthuis, Common and unique features of viral RNA-dependent polymerases. Cell Mol Life Sci 71, 4403\u20134420 (2014).","journal-title":"Cell Mol Life Sci"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"e00487-17","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase","volume":"91","author":"Abdelnabi R","year":"2017","unstructured":"R Abdelnabi, , Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase. J Virol 91, e00487-17 (2017).","journal-title":"J Virol"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1128\/JVI.03483-14","article-title":"Effective lethal mutagenesis of influenza virus by three nucleoside analogs","volume":"89","author":"Pauly MD","year":"2015","unstructured":"MD Pauly, AS Lauring, Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 89, 3584\u20133597 (2015).","journal-title":"J Virol"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","article-title":"Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance","volume":"8","author":"Beaucourt S","year":"2014","unstructured":"S Beaucourt, M Vignuzzi, Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol 8, 10\u201315 (2014).","journal-title":"Curr Opin Virol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1038\/emi.2014.80","article-title":"Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution","volume":"3","author":"Zhang X","year":"2014","unstructured":"X Zhang, , Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerg Microbes Infect 3, e78 (2014).","journal-title":"Emerg Microbes Infect"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover JB","year":"2016","unstructured":"JB Westover, , Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126, 62\u201368 (2016).","journal-title":"Antiviral Res"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"12943","DOI":"10.3390\/ijms160612943","article-title":"A structural overview of RNA-dependent RNA polymerases from the Flaviviridae family","volume":"16","author":"Wu J","year":"2015","unstructured":"J Wu, W Liu, P Gong, A structural overview of RNA-dependent RNA polymerases from the Flaviviridae family. Int J Mol Sci 16, 12943\u201312957 (2015).","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin Z","year":"2013","unstructured":"Z Jin, LK Smith, VK Rajwanshi, B Kim, J Deval, The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase. PLoS One 8, e68347 (2013).","journal-title":"PLoS One"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.celrep.2017.10.005","article-title":"Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers","volume":"21","author":"Dulin D","year":"2017","unstructured":"D Dulin, , Signatures of nucleotide analog incorporation by an RNA-dependent RNA polymerase revealed using high-throughput magnetic tweezers. Cell Rep 21, 1063\u20131076 (2017).","journal-title":"Cell Rep"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.chom.2017.09.008","article-title":"A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets","volume":"22","author":"Imai M","year":"2017","unstructured":"M Imai, , A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe 22, 615\u2013626.e8 (2017).","journal-title":"Cell Host Microbe"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1811345115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1811345115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T14:33:52Z","timestamp":1654612432000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1811345115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":50,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018,11,6]]}},"alternative-id":["10.1073\/pnas.1811345115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1811345115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"2018-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}